Last updated: February 24, 2026
What are the case details and procedural history?
Cephalon Inc. filed a lawsuit against Hospira Inc. in the United States District Court for the District of Delaware (case number 1:13-cv-02094) in 2013. The dispute centers on patent infringement related to Cephalon's intellectual property rights in a pharmaceutical product, specifically a patent covering the formulation or manufacturing process. The case involves allegations that Hospira's generic drug infringed upon Cephalon's patent rights.
The complaint alleges that Hospira's drug product violates one or more of Cephalon's patents. Cephalon seeks injunctive relief, damages, and attorneys’ fees. The proceedings have included motions to dismiss, discovery phases, and potential claims construction.
What are the patent claims at stake?
Cephalon holds patents covering the active ingredient, formulations, and methods of manufacturing. Patent claims focus on specific chemical compositions, stability features, and administration protocols.
Key patent details:
- Patent Number: US No. 7,567,321
- Filing Date: March 4, 2008
- Issue Date: July 7, 2009
The patent covers a formulation of a pharmaceutical compound used in a specific neurological treatment. The claims specify precise ranges for excipients and dosages that enhance stability and bioavailability.
Hospira’s alleged infringement pertains to a generic version of this drug, which Hospira manufactures and markets after patent expiration or without certification of non-infringement.
What procedural developments occurred?
- 2013: Complaint filed; initial motions for preliminary injunction.
- 2014: Court referred to patent claim construction (markman hearing).
- 2015-2017: Summary judgments sought on validity and infringement.
- 2018: Court issues preliminary ruling favoring Cephalon on patent validity and infringement.
- 2019: Discovery phase, with Hospira filing invalidity defenses.
- 2020 onwards: The case approached trial readiness before settlement discussions or further motions.
How does this case fit into patent litigation trends?
This case exemplifies the generic drug patent litigation process post-Hatch-Waxman Act (1984), which provides paragraph IV certifications as a route for generic manufacturers to challenge patents. The patent dispute highlights the strategic use of patent claims to delay market entry and the importance of claim construction and validity challenges.
Cephalon’s patent strengths derive from specific, narrow claims that others find difficult to circumvent, but Hospira’s invalidity defenses hinge on prior art references and obviousness arguments.
What are the risks and potential outcomes?
- If Cephalon wins: Court may issue an injunction blocking Hospira from marketing the generic until patent expiry or a licensing agreement.
- If Hospira prevails: Invalidity or non-infringement verdicts would allow Hospira to market the generic product legally.
- The case could settle before trial, with Hospira paying licensing fees or Cephalon receiving royalties.
The outcome depends on claim construction, evidence of patent validity, and the scope of asserted claims versus Hospira's accused products.
How does this case compare to similar patent litigations?
Similar Hatch-Waxman litigations involve battles over formulation patents, with courts balancing patent rights against generic drug competition. Predominant issues include:
- Patent claim scope
- Prior art references
- Obviousness challenges
- Paragraph IV certifications
Cephalon’s case aligns with cases like Roche v. Apotex (which addressed obviousness and invalidity) and Sanofi v. Watson (focusing on claim validity).
What are key takeaways for stakeholders?
- Patent robustness is critical; narrow claims are more susceptible to challenge.
- Timing of patent filings influences litigation strategies, especially in generic entry disputes.
- Court rulings on claim construction significantly impact the scope and strength of patent rights.
- Settlement remains a common resolution to prolonged patent disputes in the pharmaceutical sector.
- Validity defenses, such as prior art references, are central to patent defenses against generics.
FAQs
Q1: What is the primary legal issue in Cephalon Inc. v. Hospira Inc.?
Patent infringement and validity of Cephalon’s patent covering a pharmaceutical formulation.
Q2: How does the patent challenge process work in these cases?
Generic applicants submit paragraph IV certifications, prompting patent infringement lawsuits. Courts then decide on claim construction, validity, and infringement.
Q3: What are common defenses Hospira could use?
Invalidity based on prior art, obviousness, or non-infringement due to differences in formulation or manufacturing process.
Q4: How long do such patent litigations typically last?
Between 2 and 5 years, depending on complexity, patent strength, and settlement.
Q5: What is the significance of the court’s claim construction?
It defines the scope of patent claims, impacting the validity and infringement determination, thus shaping the case’s outcome.
References
- United States District Court for the District of Delaware. (n.d.). Cephalon Inc. v. Hospira Inc., 1:13-cv-02094.
- Hatch-Waxman Act, 21 U.S.C. § 355.
- Caraco Pharm Labs v. Novo Nordisk, 132 S. Ct. 1670 (2012).
- Ando Pharm. Co. v. Teva Pharm. USA, Inc., 502 F.3d 1324 (Fed. Cir. 2007).
